SEC F	Form 4
-------	--------

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	STATEMEN Filed	ERSHIP	
 Name and Address of Reporting Person [*]		2. Issuer Name and Ticker or Trading Symbol Arbutus Biopharma Corp [ABUS]	5. Relationship of Repo (Check all applicable)

/IB Number: 3235-0287 timated average burden urs per response: 0.5

1. Name and Addr	•	g Person [*]	2. Issuer Name and Ticker or Trading Symbol Arbutus Biopharma Corp [ABUS]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
Cousins Bru	<u>lce</u>			Director 10% Owner							
				X Officer (give title Other (specify below)							
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 07/09/2015	Exec VO & CFO							
C/O ARBUTUS BIOPHARM CORP. SUITE 100, 8900 GLENLYON PARKWAY			0//00/2010								
				ļ							
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street)				X Form filed by One Reporting Person							
BURNABY	A1	V5J 5J8		Form filed by More than One Reporting							
			—	Person							
(City)	(State)	(Zip)									
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										

1. Title of Security (Instr. 3)	Date	2A. Deemed Execution Date, if any (Month/Day/Year)	ecution Date, Transaction I					Securities Beneficially	(D) or Indirect	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned(e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		of Securities		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4			
Employee Stock Option (right to buy)	\$17.57	07/09/2015		A		75,000		(1)	03/30/2025	Common Shares	75,000	\$0	75,000	D	

Explanation of Responses:

1. The option vests as follows: 1/3 on 3/30/2016; 1/3/ on 3/30/2017; and 1/3 on 3/30/2018.

Remarks:

/s/ Bruce Cousins

** Signature of Reporting Person

12/22/2015 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.